Brought to you by 
Synosia gets rights to Novartis Pharma's rufinamide
17 Aug 2021
Executive Summary
Synosia Therapeutics (formerly Synosis Therapeutics; focused on CNS disorders) has licensed exclusive global rights--excluding Japan--to Novartis Pharma's rufinamide for anxiety disorders and bipolar mood disorders. Synosia plans to begin Phase II studies later this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synosia gets rights to Novartis Pharma's rufinamide
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice